HFPN Strategic Adviser Ed Harding discusses cardiovascular care with Health Europa Quarterly

News & Events

19 January 2022

Ed Harding, Strategic Adviser to the Heart Failure Policy Network (HFPN), recently spoke with Health Europa Quarterly (HEQ) about the key challenges affecting the diagnosis, screening and treatment of heart failure.

In the interview, which is included in issue 20 of the HEQ online publication, Ed outlined how the HFPN was founded and its role in addressing gaps in heart failure care. The conversation also turned to learnings from the inaugural Heart Failure Policy Summit in 2021, which looked at heart failure in light of health inequalities, health system sustainability and the impact of COVID-19.

The key takeaway from the discussion is the need to increase knowledge and awareness of cardiovascular disease, and to make rapid improvements in European heart failure policy. ‘If you look at studies across Europe, we know that we are not very good at helping people who live with established cardiovascular disease,’ says Ed. ‘The message I would convey to anyone reading this article is that their government, or their region, should at least have a position, even if it’s not a strategy, on heart failure.’

Read the full article: https://www.healtheuropa.eu/connecting-care-for-cardiovascular-diseases/112819/


More from News & Events

9 things we learnt from the Heart Failure Policy Summit 2022
9 things we learnt from the Heart Failure Policy Summit 2022...
13 January 2023
Last year's Summit brought together experts from the heart failure and wider health advocacy communities. Here, we reflect on some learning points....
Read article
Innovation in heart failure: how can we ensure early diagnos
Innovation in heart failure: how can we ensure early diagnos...
08 December 2022
Our ‘Innovation in heart failure: early diagnosis in community settings’ report outlines the urgent need to boost timely diagnosis and presents a variety of promising initiativ...
Read article
The Heart Failure Policy Network is an independent, multidisciplinary platform made possible with financial support from AstraZeneca, CSL Vifor, Boehringer Ingelheim and Roche Diagnostics. The content produced by the Network is not biased toward any specific treatment or therapy. All outputs are guided and endorsed by the Network’s members. All members provide their time for free. The Network is hosted by The Health Policy Partnership .